Tumor Biology · 2020 · 28 citations · 26 references
MedicineImmunologyOncologyCancer ImmunologyMetastasisPediatric OncologyAntitumor T Cell ResponsesCancer ImmunotherapyImmune Cell InfiltrationImmuno-oncology BiomarkersTumor-infiltrating LymphocytesTumor-stroma InteractionsCd8 Positive T CellsCd8+ Tumor-infiltrating LymphocytesDisease-free Survival AnalysisDisease-free Survival AssessmentInfiltrationRegional Lymph Node InvolvementTumor Immune Cell InfiltrationTumor Invasion Assessment
The abundance and location of CD8+ tumor-infiltrating lymphocytes demonstrate important facets of the anticancer immune response. CD8-expressing lymphocytes have been used in immunotherapy for multiple cancers. This study aims to determine the association between the abundance and localization of CD8+ tumor-infiltrating lymphocytes and clinical outcomes of Wilms' tumor. This retrospective study employed 42 pediatric patients diagnosed with Wilms' tumor. CD8+ tumor-infiltrating lymphocyte counts were calculated based on the mean percentage of stroma occupied by CD8+ lymphocytes at the center and the invasive border of the tumor using immunohistochemistry. CD8+ tumor-infiltrating lymphocyte counts were significantly higher in the center and the invasive border of the early-stage tumor samples. CD8+ tumor-infiltrating lymphocytes in the invasive border and tumor center positively correlated with tumor invasion, regional lymph node invasion, histological type, metastasis, and stage of the tumor. A high CD8+ tumor-infiltrating lymphocyte scores at the invasive margin of the tumor correlated with low tumor recurrence. Low CD8+ tumor-infiltrating lymphocyte scores in the two tumor regions correlated with poor prognosis and shorter disease-free survival. Overall, these findings show that patients with high CD8+ tumor-infiltrating lymphocytes are associated with better clinical outcomes. Therefore, measuring the abundance of CD8+ tumor-infiltrating lymphocytes may be useful in predicting response to cancer immunotherapies.
26
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
Hager R. Ali, Elena Provenzano, Sarah‐Jane Dawson et al. · Annals of Oncology · 2014 · 790 citations · Full text
Medicine, Immunology, Oncology +14